We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01610284
Recruitment Status : Active, not recruiting
First Posted : June 4, 2012
Last Update Posted : October 18, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )